1. 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015) Authors: Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; Melemed, A.; Carter, G.C.; Zimmermann, A.H.; Treat, J.A.; Alexandris, E.; Lee, P.; Socinski, M.A.; Perol, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3089 Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC). (September 2015) Authors: Schwartzberg, L.; Chandler, J.; Reynold, C.; Garon, E.B.; Stepanski, E.J.; Keogh, G.P.; Blankstein, K.; Schneider, J.; Korytowski, B.; Sen, R.; Coon, C.; McDonald, J.; Li, X.; McCleod, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 33LBA Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001. Issue 3 (September 2015) Authors: Soria, J.C.; Flatten, O.; Horn, L.; Felip, E.; Gandhi, L.; Hui, R.; Hellmann, M.; Leighl, N.; Zhang, J.; Kondic, A.; Rangwala, R.; Lubiniecki, G.M.; Garon, E.B. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Issue 16 (November 2015) Authors: Giaccone, G.; Bazhenova, L.A.; Nemunaitis, J.; Tan, M.; Juhász, E.; Ramlau, R.; van den Heuvel, M.M.; Lal, R.; Kloecker, G.H; Eaton, K.D.; Chu, Q.; Dunlop, D.J.; Jain, M.; Garon, E.B.; Davis, C.S.; Carrier, E.; Moses, S.C.; Shawler, D.L.; Fakhrai, H. Journal: European journal of cancer Issue: Volume 51:Issue 16(2015:Nov.) Page Start: 2321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Capmatinib response in patients with advanced non–small cell lung cancer (NSCLC) harboring focal MET amplifications: Analysis from the phase 2, multicohort GEOMETRY mono-1 study. (October 2022) Authors: Wolf, J.; Garon, E.B.; Groen, H.J.M.; Tan, D.S.W.; Le Mouhaer, S.; Riester, M.; Ji, L.; Robeva, A.; Fairchild, L.; Boran, A.; Heist, R.S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗